Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Zepbound stories

Nov 16, 2026

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00
Nov 14, 2026

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Eli Lilly released new clinical trial data for its obesity drugs at the ObesityWeek 2026 medical conference, showing weight loss benefits, though full results have not yet been published.

Nov 14, 2026·2 sources
00
Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 4, 2026

Novo Nordisk raises 2026 outlook for third time on strong Wegovy pill sales

Novo Nordisk raised its full-year forecast for the third time in 2026 after third-quarter sales of its Wegovy weight-loss pill reached $807 million, beating analyst expectations and driving stronger-than-expected quarterly earnings.

Nov 4, 2026·4 sources
00
Oct 29, 2026

Eli Lilly raises revenue forecast on weight-loss drug demand

Eli Lilly raised its full-year revenue forecast by $5 billion and beat third-quarter profit estimates driven by booming demand for its injectable weight-loss drugs, particularly among older Americans.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Oct 26, 2026

Eli Lilly wins court ruling allowing weight-loss drug ads against Novo Nordisk

A US court denied Novo Nordisk's request to temporarily block Eli Lilly from using advertisements claiming its obesity drugs are more powerful, a setback for Novo as it battles to regain market share.

Oct 26, 2026·2 sources
00
Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00
Aug 12, 2026

Eli Lilly escalates legal fight against black market for experimental weight-loss drug retatrutide

Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.

Aug 12, 2026·2 sources
00
Jul 14, 2026

Study finds frailty risks with GLP-1 drugs in older adults

A large study found potential signs of frailty in older adults taking Eli Lilly's Zepbound may signal relatively high risks for adverse outcomes, raising concerns about GLP-1 obesity drug use in elderly populations.

Jul 14, 2026·1 source
00
May 28, 2026

CVS Health Restores Coverage of Eli Lilly's Zepbound and Adds New Obesity Pill to Drug Plans

CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.

May 28, 2026·2 sources
00
May 3, 2026

Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1

Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.

May 3, 2026·1 source
00

Top claims

  • ▪Almost 80 percent of children aged 6 to under 12 given Wegovy in Novo Nordisk's trial reduced their body mass index by at least 10 percent over 68 weeks
  • ▪In the 68-week trial, 40 percent of children aged 6 to under 12 taking Wegovy were no longer classified as having obesity, compared with none in the placebo group
  • ▪As of November 16, 2026, Novo Nordisk has not announced if or when it will file for regulatory approval to treat children under 12 with Wegovy

Subtopics

Eli Lilly13Drug Policy, Pricing & Approval6Novo Nordisk6Obesity treatment6Weight loss drugs6Clinical trials4GLP-1 medications4Lifestyle, Wellness and Nutrition4Retatrutide4Weight loss medications & GLP-1 drugs4Weight management4Drug safety3Foundao3Pharma3Pharmaceutical Industry3Blood sugar & insulin2GLP-12GLP-1 / Weight-Loss Medications2GLP-1 drugs2GLP-1 receptor agonists2Pharmaceutical earnings2Adolescent health1Age related cognitive decline1Childhood obesity1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories